Viveve Medical, Inc. (NASDAQ:VIVE) – Research analysts at Zacks Investment Research lowered their Q3 2017 EPS estimates for Viveve Medical in a report released on Monday. Zacks Investment Research analyst B. Marckx now expects that the company will earn ($0.43) per share for the quarter, down from their prior forecast of ($0.32). Zacks Investment Research also issued estimates for Viveve Medical’s Q4 2017 earnings at ($0.46) EPS, FY2017 earnings at ($1.97) EPS, FY2018 earnings at ($1.38) EPS, FY2019 earnings at ($1.11) EPS and FY2020 earnings at ($0.94) EPS.

A number of other research firms also recently weighed in on VIVE. Cowen and Company reissued a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research report on Thursday, August 17th. Maxim Group reissued a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research report on Friday, August 11th. ValuEngine raised shares of Viveve Medical from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Raymond James Financial, Inc. started coverage on shares of Viveve Medical in a research report on Thursday, May 25th. They set an “outperform” rating and a $10.00 target price for the company. Finally, B. Riley reissued a “buy” rating and set a $10.00 target price on shares of Viveve Medical in a research report on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Viveve Medical currently has a consensus rating of “Buy” and an average target price of $12.80.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Weighs in on Viveve Medical, Inc.’s Q3 2017 Earnings (VIVE)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/24/zacks-investment-research-weighs-in-on-viveve-medical-inc-s-q3-2017-earnings-vive.html.

Shares of Viveve Medical (NASDAQ VIVE) opened at 5.23 on Thursday. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The stock has a 50 day moving average price of $6.59 and a 200 day moving average price of $6.48. The company’s market capitalization is $101.49 million.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.21. Viveve Medical had a negative net margin of 266.93% and a negative return on equity of 244.96%. The company had revenue of $3.08 million during the quarter, compared to the consensus estimate of $3.24 million. During the same quarter in the prior year, the company posted ($0.66) earnings per share. The company’s revenue for the quarter was up 97.4% on a year-over-year basis.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC increased its position in Viveve Medical by 48.1% in the first quarter. Stonepine Capital Management LLC now owns 3,849,711 shares of the company’s stock worth $24,256,000 after buying an additional 1,250,000 shares in the last quarter. HighTower Advisors LLC increased its position in Viveve Medical by 33.2% in the second quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock worth $12,379,000 after buying an additional 430,033 shares in the last quarter. Perceptive Advisors LLC bought a new position in Viveve Medical during the first quarter worth $5,942,000. Wexford Capital LP increased its position in Viveve Medical by 23.9% in the first quarter. Wexford Capital LP now owns 777,124 shares of the company’s stock worth $4,919,000 after buying an additional 150,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Viveve Medical by 135.4% in the second quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock worth $3,232,000 after buying an additional 258,912 shares in the last quarter. 62.31% of the stock is owned by hedge funds and other institutional investors.

In related news, CFO Scott Durbin bought 5,000 shares of Viveve Medical stock in a transaction dated Wednesday, August 23rd. The stock was purchased at an average cost of $5.25 per share, with a total value of $26,250.00. Following the transaction, the chief financial officer now directly owns 11,568 shares of the company’s stock, valued at $60,732. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 35.10% of the stock is owned by corporate insiders.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Earnings History and Estimates for Viveve Medical (NASDAQ:VIVE)

Receive News & Stock Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related stocks with our FREE daily email newsletter.